COMMUNIQUÉS West-GlobeNewswire

-
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
22/09/2025 -
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
22/09/2025 -
Yatiri Bio Receives Grant to Advance Proteomics Interoperability in Cancer Research
22/09/2025 -
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
22/09/2025 -
Fierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025
22/09/2025 -
WORK Medical Technology Group LTD Partners with Wuxi Branch of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine to Develop AI-Applications in Healthcare
22/09/2025 -
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index
22/09/2025 -
PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes
22/09/2025 -
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
22/09/2025 -
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress
22/09/2025 -
Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management
22/09/2025 -
Baylor Genetics to Showcase the Expanding Role and Clinical Value of Genetic Testing in Pediatric Neurology at the 2025 Child Neurology Society Annual Meeting
22/09/2025 -
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22/09/2025 -
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22/09/2025 -
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics
22/09/2025 -
First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease
22/09/2025 -
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22/09/2025 -
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22/09/2025 -
Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain
22/09/2025
Pages